{
    "clinical_study": {
        "@rank": "19817", 
        "arm_group": [
            {
                "arm_group_label": "Period 1", 
                "arm_group_type": "Experimental", 
                "description": "240 mg tafamidis arm"
            }, 
            {
                "arm_group_label": "Period 2", 
                "arm_group_type": "Experimental", 
                "description": "480 mg arm"
            }, 
            {
                "arm_group_label": "Period 3", 
                "arm_group_type": "Experimental", 
                "description": "TBD dose"
            }
        ], 
        "brief_summary": {
            "textblock": "This study in healthy male and female volunteers will investigate the safety and\n      tolerability of three increasing oral doses of tafamidis"
        }, 
        "brief_title": "Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "TTR Cardiomyopathy", 
        "condition_browse": {
            "mesh_term": "Cardiomyopathies"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy, males or females, 21 to 55 years old.\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2.\n\n        Exclusion Criteria:\n\n        Evidence or history of clinically significant hematological, renal, endocrine, pulmonary,\n        gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease\n        (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at\n        the time of dosing).\n\n        Condition affecting drug absorption. Blood pressure or ECG abnormalities. Recent treatment\n        with an investigational, prescription, or non-prescription drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01655511", 
            "org_study_id": "B3461040", 
            "secondary_id": "B3461040"
        }, 
        "intervention": [
            {
                "arm_group_label": "Period 1", 
                "description": "240 mg, solution, single dose", 
                "intervention_name": "Tafamidis", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Period 2", 
                "description": "480 mg, solution, single dose", 
                "intervention_name": "Tafamidis", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Period 3", 
                "description": "TBD dose will be a single dose if < 720 mg or a loading dose followed by additional dose if > 720 mg.", 
                "intervention_name": "Tafamidis", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Pharmacokinetic", 
            "pharmacodynamic"
        ], 
        "lastchanged_date": "September 26, 2012", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3461040&StudyName=Safety%20And%20Pharmacokinetic%20Assessment%20Of%20Orally%20Administered%20Tafamidis%20In%20Healthy%20Volunteers"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Singapore", 
                    "country": "Singapore", 
                    "zip": "188770"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Singapore"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Randomized, Double-Blind, Crossover, Ascending Dose-Tolerance Study To Assess The Safety And Pharmacokinetics Of Tafamidis Doses Greater Than 120 Mg As Oral Solution In Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "To evaluate the safety and tolerability of orally administered tafamidis in healthy volunteers at escalating doses >120 mg. Safety assessments will include spontaneous reporting of adverse events, concomitant medications, physical examination,", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0 and Day 6"
            }, 
            {
                "measure": "vital signs, ECGs, and clinical laboratory tests.", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0 and Day 6"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01655511"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax - Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs"
            }, 
            {
                "measure": "tmax - Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs"
            }, 
            {
                "measure": "AUC0-24 - AreArea under the Concentration-Time Curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs"
            }, 
            {
                "measure": "AUClast - Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]", 
                "safety_issue": "No", 
                "time_frame": "0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs"
            }, 
            {
                "measure": "AUCinf - Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - \u221e)]", 
                "safety_issue": "No", 
                "time_frame": "0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs"
            }, 
            {
                "measure": "t\u00bd - Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs"
            }, 
            {
                "measure": "Transthyretin blood concentration in mg/dL", 
                "safety_issue": "No", 
                "time_frame": "Days 0,1,2,3,4,5,6"
            }, 
            {
                "measure": "Transthyretin stabilization (%)", 
                "safety_issue": "No", 
                "time_frame": "Days 0,1,2,3,4,5,6"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}